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INCIDENCE AND PREDICTORS OF PREMATURE VENTRICULAR COMPLEXES 
FOLLOWING CATHETER ABLATION FOR ATRIAL FIBRILLATION 
JOSHUA HARVEY 
ABSTRACT 
Background 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, and previous studies 
have focused on the epidemiology, mechanisms and risk factors for this global 
disease (Ryder and Benjamin 1999). One of the most common triggers for AF is 
believed to be premature atrial contractions (PACs) usually arising from the 
pulmonary veins of the left atrium, but the relationship between AF and premature 
ventricular complexes (PVCs) is not well understood. Studies investigating the 
triggers of premature beats in both the atria and ventricles are similar, so it is 
possible that treatment for one arrhythmia may affect the incidence of another. It is 
hypothesized that due to commonly shared mechanisms of triggered activity or 
automaticity between PACs and PVCs, and shared risk factors, that patients with AF 
undergoing treatment with catheter ablation may be prone to develop PVCs. 
Objective 
To investigate the incidence of clinically detected PVCs among patients undergoing 
catheter ablation for AF, and clinical predictors of PVC development in this cohort of 
patients.  We also aim to evaluate if incident PVC detection is associated with 
recurrent AF following AF ablation in a cohort of 317 patients receiving treatment at 
a single academic medical center.  
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Methods 
 A total of 375 patients undergoing AF ablation from 2009-2012 were reviewed, and 
patients that underwent repeat ablations were excluded, yielding 317 patients for 
analysis. T-tests and Chi-squared analyses were used in univariate analyses to test 
for significance between characteristics of AF patients who did and did not develop 
PVCs. Kaplan-Meier analyses and Cox proportional hazards models were used for 
univariate and multivariate survival analyses, respectively, to assess the risks of 
incident PVC development.   
Results 
Of 317 patients with AF undergoing pulmonary vein isolation (PVI) ablation, 36.3% 
developed clinically detectable PVCs following ablation.  A history of clinically 
evident PVC prior to catheter ablation for AF was associated with an 83% increase 
in risk of incident PVC development (HR=1.83, 95% CI 1.02-3.26, p=0.041). 
Additionally, a history of prior angioplasty, stent, or percutaneous coronary 
intervention (PCI) was associated with a 73% decreased risk of incident PVCs 
(HR=0.27, 95% CI 0.08-0.88, p=0.03). In patients with a history of PVC prior to 
ablation, or who developed PVCs after ablation, there was no significant difference 
in the risk of AF recurrence (HR=1.01, 95% CI 0.70-1.46, p=0.96; and HR=1.09, 95% 
CI 0.78-1.53, p=0.60, respectively). 
Conclusions: 
Over 1 in 3 patients develop clinically detected PVCs following catheter ablation.  
Predictors of incident PVC development include a history of PVC, whereas a history 
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of angioplasty, stent, or PCI was associated with less incident PVC development.  
Furthermore, there was no significant association between both a history of PVC or 
incident PVC and risk of recurrent AF following ablation.    
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INTRODUCTION 
This thesis will begin with a brief exploration of the most common cardiac 
arrhythmia Atrial Fibrillation (AF), its various classifications, and how it is 
diagnosed. Following this, the focus will shift to an overview of the epidemiology of 
AF; detailing both its prevalence and incidence worldwide, as well as its burden on 
the US healthcare system. Then the mechanism of AF and the role of premature 
atrial contractions (PACs) as a trigger, its associated comorbidities, and the various 
modern-day modalities of treatments including medical therapy versus procedural 
therapy (catheter ablation) will be discussed. Finally, there will be a brief 
examination of the same factors related to premature ventricular complexes (PVCs) 
emanating from the ventricular myocardium of the heart. Both conditions will be 
considered together in conjunction with an original analysis of data from a 
retrospective chart review to assess the possible interplay of PACs and triggered AF 
and its associated risk in the development of PVCs, or the association of PVCs and 
the risk of developing recurrent AF.  
 
Atrial Fibrillation: Classifications and Diagnostic Evaluations 
AF is a supraventricular arrhythmia that causes uncoordinated and chaotic 
atrial activity via disorganized electrical activation of right and left atrial 
myocardium, and can eventually lead to a decline in mechanical function of the atria 
(Fuster et al. 2001). It is a progressive disease that is often classified by subtype of 
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duration including paroxysmal, persistent, and permanent AF.  Paroxysmal AF is 
defined as AF that terminates spontaneously or via intervention within seven days, 
while Persistent AF is continuous, lasting longer than seven days. Long-standing 
persistent AF is persistent AF that has lasted for more than 12 months. Permanent 
AF is a term used when both the patient and physician decide to cease any 
treatment or the pursuit of maintaining sinus rhythm in an AF patient (January et al. 
2014; Kirchhof et al. 2016). AF commonly advances from short, sporadic episodes to 
sustained persistent epochs that are harder to control over time (Kirchhof et al., 
2016). Other comorbidities associated with AF have been found to alter the physical 
structure of the atria due to an increased burden; the longer that AF has been 
present, the more drastic the changes in the atria (Allessie et al. 2001; Wilber 2009). 
These physical changes along with other mechanisms to be later discussed in 
further detail may cause an increase in both the appearance and duration of this 
arrhythmia.  
 In evaluating the presence or extent of AF in patients, the two main 
diagnostic tools used are Electrocardiograms (ECG) and Transesophageal 
Echocardiograms (TEE). The use of ECG may help reveal many diseases of the heart 
that can be either electrical or nonelectrical, such as left ventricular hypertrophy, 
coronary heart disease, and various arrhythmias (Patel et al. 2000). The primary 
characteristics that characterize AF on an ECG are a lack of discernable P waves that 
are replaced by rapid oscillations or fibrillatory (f) waves, and irregular RR intervals 
(Fuster et al. 2001; Patel et al. 2000). Figure 1 shows a classic waveform of AF on an 
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ECG (Appendix A). The TEE visualizes the heart’s atria as well as its ventricular 
function, and can be used to evaluate valvular disease. The primary purpose of the 
TEE in AF patients is for the detection of clots in the left atrial appendage (LAA), and 
is commonly performed prior to procedures of the left atrium, such as cardioversion 
or catheter ablation to avoid the risk of clot dislodgement and ischemic stroke 
(Annals of Internal Medicine, 1992). Further details can be enumerated regarding 
the classifications not mentioned in this thesis, as well as diagnostic tools used in 
the identification of AF in patients. 
 
Epidemiology of AF  
 AF is the most common cardiac arrhythmia in the world, with the lifetime 
risk for developing AF being approximately 1 in 4 for both men and women over the 
age of 40 (Lloyd-Jones et al. 2004). This strikingly high lifetime risk presents a clear 
and present need for elucidating the currently unknown mechanisms of this 
arrhythmia. Adjusting for common comorbidities of AF such as age, hypertension, 
and congestive heart failure, men were found to be 1.5 times more likely to develop 
AF than women (Benjamin et al. 1994). While the risk of developing AF is greater in 
men, women represent a greater number of cases of AF, due to their longer life 
expectancy (Ryder and Benjamin, 1999). There is also a higher risk of incident AF in 
Whites for both genders than in Blacks, Hispanics, and Asians (Dewland et al. 2013, 
Amponsah et al. 2013). This lower incidence in non-whites is surprising, and is 
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deemed a “racial paradox”, considering the much higher rates of established risk 
factors for AF such as hypertension, diabetes, and left ventricular hypertrophy in 
these populations (Amponsah et al. 2013, Alonso et al. 2009). 
In the United States, the geographic distribution of AF hospitalizations is 
predominantly concentrated in the South at 38.5%, with the next highest region 
being the Midwest at 24.9% (Patel et al. 2014). The high rates of AF in the South 
heavily supports the excess stroke mortality seen in the Southeastern region of the 
United States, a region that is known as the “Stroke Belt", as well as the “Heart 
Failure Belt” (Howard 1999). While the underlying causes for the high incidence of 
stroke and heart failure in this region are not completely understood, it is possible 
that AF plays a large role in this phenomenon, given that it is such a high risk factor 
for stroke (Mujib et al. 2011). AF has been found to be the most common arrhythmia 
following coronary artery bypass graft (CABG) and valvular surgeries (Alqahtani 
2010). Given the increased incidence of heart failure and related surgeries in the 
Southern region of the US, the increased rates of AF in the same region may be 
related (Alqahtani 2010). 
The incidence of AF has been reported to be relatively stable over the span of 
the last three decades, but the overall prevalence has increased annually by an 
average of 5%, and is estimated to increase as much as three-fold worldwide in the 
coming decades (Piccini et al. 2012; Morin et al. 2016). This rate of developing AF 
was also found to increase with an increase in age; with a greater rate of change 
seen in patients 90 years or older in comparison to patients between the ages of 66 
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and 69 years (Piccini et al. 2012). This phenomenon is further supported by the 
Framingham Heart Study, which found that both men and women doubled their risk 
of developing AF with each decade of life (Benjamin et al. 1994). Despite these 
quantitative measurements in various studies, it is believed that AF prevalence is 
actually underestimated, due to AF often being asymptomatic. Asymptomatic AF has 
been found to occur far more frequently than symptomatic AF, opening up the 
potential population of patients suffering from AF to rates previously unmeasured 
(Page et al. 1994). Considering continual advancements in medicine, technology, 
and efficacy of care, it can be safely assumed that the prevalence of AF will only 
increase in the coming years. 
 
The Costs and Burden of Atrial Fibrillation  
In 2011, healthcare expenditures for AF alone were estimated to be 
approximately $6 billion, and approximately $26 billion total with other 
cardiovascular related costs included, making it a substantial burden on the US 
healthcare system (Coyne et. al 2006., Kim et al. 2011). While this estimated cost 
may seem high, Coyne et al. did not account for the costs associated with treating AF 
in home healthcare and skilled nursing facilities, which would contribute even more 
to the already high costs (Sheikh et al. 2015). In 2008, the mean direct costs per 
patient over the course of a year were $20,670 for AF patients and $11,965 for 
control patients; an $8,705 difference that was primarily accounted for by inpatient 
services rather than outpatient services (Kim et al. 2011). If AF could be prevented 
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or more efficiently treated, these costs could be lowered, alleviating costs to both 
patients and the US healthcare system alike.   
It is believed that 91% of AF-related thrombi originate in the LAA, 
highlighting the increased risk of stroke in AF patients (Blackshear & Odell 1996). 
This increased risk of stroke directly contributes to increased patient costs due to 
the pursuit of anticoagulant treatment in AF patients to lower this risk; the drugs 
used in the majority of AF patients being aspirin, or warfarin (Gottlieb & Salem-
Schatz 1994). Additionally, the advent of non-vitamin K antagonist oral 
anticoagulants for treatment of stroke risk reduction in AF patients has changed the 
landscape of pharmacologic agents used for this reason, and the costs associated 
with care (Kalabalik et al. 2015). For patients that have a contraindication to 
anticoagulant therapy or prefer to stay off of these medications, recent procedures 
that aim to close the LAA, such as the Watchman or LARIAT procedure, have been 
shown to be an efficacious albeit costly alternatives (Holmes et al. 2009; Bartus et al. 
2013). All of these points make up just a brief overview of the multitude of different 
costs that are directly and indirectly associated with AF, and can be further detailed 
to highlight how much this arrhythmia continues to burden the healthcare system. 
 
Mechanism of AF 
The onset of AF is thought to come from certain triggers that induce the 
arrhythmia, and substrates of the atria that perpetuate it. Examples of these triggers 
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are premature atrial contractions (PAC), atrial stretch, and ectopic foci located in 
various regions of the atria (Allessie et al. 2001). Haissaguerre et al. first discovered 
the relationship of ectopic foci originating in the pulmonary veins (PV) leading to 
AF, and the ability to terminate these aberrant signals by electrically isolating the PV 
from the rest of the atrium via Radiofrequency Catheter Ablation (RFCA) 
(Haissaguerre et al. 1998). While AF can occur from single or ectopic foci in atrial 
tissue around the PV, it is the electrical and structural remodeling due to various 
associated maladies that may bolster the transition from a Paroxysmal to Persistent 
classification of AF (Allessie et al. 2001). The remodeling of substrate can be either 
electrical or physical, commonly caused by a volume overload typically seen in 
diseases such as congestive heart failure and hypertension (Franz 2000). This 
increased load in the atria leads to an overstretching of atrial myocytes, activating 
stretch activated channels (SAC) that may directly affect the excitability of nearby 
cells, allowing for the initiation or potentiation of AF (Sackin 1995, Schotten et al. 
2011). It is due to these changes in ion channels and the sporadic activity of 
surrounding cells that gives rise to various foci. As previously established, the 
changes in both the mechanical and physical properties of the atria in AF patients 
may advance over time, and this mechanism may help elucidate why AF tends to 
eventually progress to more advanced stages. 
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Associations and Comorbidities 
While many comorbidities have been identified as risk factors or predictors 
of AF, this section highlights some of the most important being currently 
investigated. 
One potentially modifiable and heavily studied risk factor in particular is 
obesity. It has been suggested that there exists an “obesity paradox”, such that 
patients with a higher body mass index (BMI) exhibit a lower risk of death in 
cardiovascular illnesses such as heart failure (Oreopoulos et al. 2008, Ardestani et 
al. 2010). Previous studies have tried to determine if AF is one of the diseases within 
the scope of this paradox, and some have found that there is no link between the 
two conditions (Benjamin et al. 1994, Krahn et al. 1995, Ardestani et al. 2010). 
However, it has been noted that many of these studies have limitations such as non-
representative populations, short term follow-up periods, and a lack of 
echocardiographic data (Wang et al. 2004). A large population from the 
Framingham Heart Study was analyzed, and the findings indicate that obesity is 
indeed a risk factor for AF, with a 4% increase in risk of AF per 1-unit increase in 
BMI, and an overall 50% increase in risk for obese patients compared to controls 
(Wang et al. 2004). In 2008, overweight and obesity rates among US adults were 
34%, respectively, and the trend was increasing (Flegal et al. 2010). This increasing 
trend paired with a known risk highlights the importance for understanding any 
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links between obesity and AF, and identifying it as a risk factor that may be 
modified.  
Another risk factor that has been investigated in conjunction with AF is 
glomerular filtration rate (GFR), an index of the kidney’s ability to filter properly. 
Watanabe et al. investigated rates of AF and kidney dysfunction in a large cohort of 
patients (n=235,818), and found that kidney dysfunction not only increased rates of 
AF onset, but also that AF increased rates of kidney disease (Watanabe et al. 2009). 
These diseases directly related to each other may be due to a common pathway 
shared between risk factors that are seen in both diseases, namely hypertension, 
heart failure, and thromboembolism (Watanabe et al. 2009).  
Closely connected, AF has been found to occur in more than half of HF 
patients, and HF occurs in more than one third of AF patients, the idea that the 
causal pathway between these two disease processes may be complicated 
(Santhanakrishnan et al. 2015). Similar to GFR, HF also shares various risk factors 
with AF, and it is possible that a common underlying mechanism may be at play. 
These are just some examples of the comorbidities associated with AF, and there are 
many others that have been identified as risk factors and predictors for this 
arrhythmia. 
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Treatment modalities of AF  
In the treatment of AF, the main therapeutic strategies considered are rate 
control and rhythm control. Rate control involves the use of drugs that slow the 
conduction across the atrioventricular (AV) node, such as beta blockers, calcium-
channel blockers, and digoxin. Rhythm control involves the use of anti-arrhythmic 
drug therapy or ablation procedure (Pritchett 1992). There are pros and cons to 
each therapeutic strategy, the advantages to rate control being the avoidance of side 
effects typically seen in antiarrhythmic drugs, or complications from procedures. 
The main advantage of rhythm control is remaining free from the arrhythmia and 
symptoms associated with the fibrillating atria or fast ventricular rate associated 
with AF (Piccini & Fauchier 2016). Whether the strategy is rate or rhythm control, 
pharmacological intervention is traditionally attempted earlier in treatment before 
procedures are attempted (Jaïs et al. 2008). However, the efficacy of catheter 
ablation has been reported in various studies, presenting it as a viable option earlier 
in the course of treatment than may be often decided (Calkins et al. 2007). Although 
there are various methods of ablation to treat arrhythmias of the heart, the scope of 
this paper will focus on RFCA, more specifically, pulmonary vein isolation (PVI), as it 
has been established as the main therapeutic approach for AF in contemporary 
practice. 
The PV were identified to be a primary source of ectopic foci and 
arrhythmias from these structures were found to be successfully terminated when 
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the PV were isolated via RFCA (Haissaguerre et al. 1998). The specific procedure 
used is referred to as segmental, or ostial pulmonary vein isolation, because the 
triggers for AF are generated in the ostium of the pulmonary veins (Oral et al. 2002). 
In this procedure, a computerized tomography (CT) scan is used to recreate the 
anatomy of the atria and PV. An electrode catheter is then passed through the 
femoral vein and into the heart, where manual pacing of the heart can occur via a 
stimulator. The origin of the aberrant trigger for AF is identified (or may be 
empirically assumed to arise from the PVs) and radiofrequency energy is delivered 
from the catheter at a maximum temperature of approximately 50-52º C, and a 
radiofrequency energy ranging from 30 KHz to 1.5 MHz (Haissaguerre et al. 2000; 
Oral et al. 2002). This technique is continued until the PV are electrically isolated 
from the rest of the atria, thus preventing the triggers that may initiate AF from 
entering the atria.  
Given the different modalities of treatment for AF, the best route is ultimately 
what the patient and physician decide is the most desirable. For some patients the 
symptoms may not be deleterious enough to warrant an ablation procedure, while 
others may have a contraindication or no desire to be on anti-arrhythmic drugs. 
With various treatment methods available today and advancements in care, the 
variations in quality of life between the different options may be a more promising 
factor in deciding the mode of care. Supporting this idea, ablation procedures have 
been found to increase quality of life, ejection fraction, and exercise duration post-
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ablation (Wood et al. 2000; Thrall et al. 2006). With a better measure of quality of 
life and a reported increase in efficacy of AF treatment, ablation procedures may be 
a decidedly promising option for patients to consider.  
 
AF and PVC: Connecting the dots 
Previous studies have determined that premature atrial contraction (PAC) 
count is a predictor of AF and is a risk factor that may be treated to reduce risk of AF 
(Dewland et al. 2013). Perhaps even more significant, PACs have been found to 
directly trigger AF as the initiating beat (Haissaguerre et al. 1998). PACs arise due to 
triggered activity or automaticity, and a similar mechanism may be responsible for 
ectopic foci in the ventricular myocardium as manifested by PVCs.  While PACs are 
correlated with AF, there have not been many studies investigating PVCs as a risk 
factor for AF, or vice versa. One study investigating the incidence of PVCs after 
ablation found that the risk of AF development over 15 years was more than 90% in 
patients that had more than 32 PVCs per hour (Patel et al. 2014). This study had a 
relatively small sample to investigate and in light of the lack of studies on incident 
PVC following AF ablation, it may help to highlight other commonly shared aspects 
between the two.  
Continuing, a high-frequency of PVCs are associated with a significantly 
increased risk of onset of AF (Watanabe et al. 2009). With this in mind, is it possible 
that a recurrence of AF following treatment is associated risk of PVC burden? It has 
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also been suggested that frequent PVC’s may cause a remodeling of the heart, 
coinciding with previously noted mechanisms of structural remodeling acting as a 
substrate for arrhythmias, namely AF (Agarwal et al. 2010). Taking into 
consideration that a history PVCs not only increases the risk of AF, but also 
contributes to conditions that may propagate this arrhythmia calls into question 
whether or not treating AF via catheter ablation affects development of PVCs 
afterwards.  
The remainder of this thesis will be centered on investigating: PVCs, original 
clinical research involving AF patients that have undergone a PVI procedure, and 
what predictors, including AF, are present as significant risks for development of 
PVC in these patients. It is hypothesized that patients being treated for AF via PVI 
will have high rate of developing incident PVCs, and these PVCs may be significantly 
correlated with recurrence of AF in patients after PVI ablation. Before reviewing the 
chart data regarding this hypothesis, more information will be briefly reviewed on 
PVCs to support the proposed reasoning for their direct association with AF.  
 
Mechanism and frequency of PVCs 
In order to fully illustrate the mechanism of PVCs, the concept of triggered 
activity and its roots must be introduced. The action potential in cardiac cells can be 
prolonged or followed by electrical activity termed “afterdepolarizations” 
(Antzelevitch and Burashnikov 2011). There are two main types of 
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afterdepolarizations: the Early afterdepolarization (EAD) and the Delayed 
afterdepolarization (DAD). Figure 2 illustrates the different phases of an action 
potential in the myocardium (Appendix A). The EAD usually occurs between phase 2 
and phase 3 of the cardiac potential and serves to slow its return to resting 
potential, while the DAD occurs after full repolarization (Antzelevitch and 
Burashnikov 2011). When either of these afterdepolarizations is sufficient enough 
to bring the membrane to threshold potential, an action potential occurs and is 
referred to as triggered activity (TA). 
The spontaneous potentials initiated by TA cause the extra beats that serve 
as the root of the various arrhythmias seen in the heart. TA has been shown to be 
the overall mechanism responsible for initiating atrial and ventricular tachycardias, 
as well as PVCs, by modulating different ion channels within cardiac myocytes (Liu 
et al. 2016; Stambler et al. 2003; Shimoike et al. 1999). More specifically, DAD-
dependent TA has been observed to be the specific trigger in the initiation of both 
atrial tachycardia and PVCs (Hluchý et al. 1992; Stambler et al. 2003). Figure 3 
shows the ECG waveform of a common PVC that may be caused by DAD-dependent 
TA (Appendix A). Extrapolating from these findings, it is possible that PACs may be 
initiated by the same type of TA that creates PVCs, except in atrial myocardium.  
Given that TA in the atrium may have similar characteristics as TA in the ventricle, 
and because it has been established that PACs can directly initiate AF, the 
hypothesis that PVCs and AF may be directly related is further supported. 
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Epidemiology of PVC 
Unlike other conditions of the heart, PVCs are not exclusive to diseased 
patients, and are commonly found in otherwise healthy men and women (Brodsky 
et al. 1977; Sobotka et al. 1981). The overall prevalence of PVCs is 6%, and they are 
seen more frequently in men, African Americans, and those with heart disease 
(Simpson Jr et. al 2002).  Supporting the suggested link between PVCs and AF are 
population-based studies that show strong associations of PVCs with other 
cardiovascular diseases such as sudden cardiac death, coronary heart disease and 
myocardial infarction (Abdalla et al. 1987; Bikkina et al. 1992).  Because they are 
commonly seen in healthy and diseased patients alike, their association should be 
investigated further. 
 
Strategies for treatment 
Like AF, PVCs can be treated by both pharmacologic therapy and ablation. 
Like atrial fibrillation, drugs that are often considered for treatment of ventricular 
ectopic beats are beta blockers, calcium-channel blockers, and Antiarrhythmic drugs 
(AAD). Specific treatment strategies depend on further evaluation of possible 
presence of underlying conditions that may be causing the PVC’s. For example, when 
considering AAD therapy, the medication prescribed often depends on preexisting 
conditions the patient may have, such as coronary heart disease. With preexisting 
heart conditions such as heart failure or coronary artery disease, the patient should 
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not be prescribed Class Ic AADs, such Flecainide or Propafenone, due to an 
increased risk of mortality or arrhythmia (Echt et al. 1991). In these patients, one 
alternative treatment could be ACE inhibitors, which were found to not only treat 
the underlying disease by regressing the hypertrophy of the left ventricle, but also 
decreased the number of PVC’s that occurred (González-Fernández et al. 1993).  For 
patients that may have a contraindication to ACE inhibitors or would just prefer a 
separate AAD option, Sotalol, a Class III AAD, was also deemed efficacious for PVC 
suppression when Class 1c AADs were not suitable options (Anastasiou-Nana et al. 
1991). These are just a few specific examples of the treatment options available for 
those burdened with PVCs. It is clear that the treatment options for PVCs intersect 
with those targeting AF, alluding to a possible mechanism that is shared between 
them. 
 
Ablation of PVC 
For patients that remain symptomatic after attempting antiarrhythmic 
treatment or beta blockers for PVCs, RFCA is a very promising option for reducing 
the number of PVCs (Lamba et al. 2014; Lauck et al. 1999; Chovancik et al. 2006; 
Raungratanamporn O et al. 1998). PVC ablation has been deemed effective, such that 
the burden of PVC has been reduced at 3 months post-ablation when PVC does not 
recur within 12 hours following the procedure (Baser et al. 2014). In addition to 
reducing the number of PVCs, RFCA has also been efficacious in reversing 
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abnormalities stemming from frequent PVCs, namely non-ischemic cardiomyopathy 
(El Kadri et al. 2015; Yarlagadda et al. 2005). Common risk factors for AF that are 
shared with PVC may be associated with subsequent development of PVCs even 
after treatment for AF, and will be investigated further. 
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SPECIFIC AIMS 
Specific aims of the following thesis include: 
1. Exploring the various aspects that make up atrial fibrillation and premature 
ventricular complexes including, but not limited to: mechanisms, 
epidemiology, and treatment. 
2. Performing a retrospective review of patients that have undergone AF 
ablation and determine the incidence of developing clinically evident PVCs 
and associated predictors of incident PVCs. 
3. Using the aforementioned analyses in conjunction with current literature to 
examine the hypothesis that patients undergoing AF ablation have a 
significant risk of developing PVCs.
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METHODS 
Data source 
Patients from a single academic center (UC San Diego Medical Center) 
between October 2009 and February 2012 were reviewed for data collection and 
analysis. Specific characteristics and outcome measures were collected via 
retrospective review of electronic medical records.   
 
Study Population 
All patients undergoing ablation for AF after October 12th, 2009 were 
considered for analysis (n=1008). Of the patients who had a complete review of 
their medical records at UCSD (n=375), those patients undergoing a first ablation 
for AF were included in the analysis (n=317). 
 
Outcomes 
The primary outcome of our analysis was incident PVC development in 
patients after undergoing PVI ablation for AF.  Incident PVC development was 
defined as any PVC noted on an ECG or Holter Monitor in a patient’s medical chart 
following ablation. Secondary outcomes included recurrence of any atrial 
arrhythmia following the 3 month blanking period post-ablation in patients with 
and without incident PVC development 
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Definitions of Arrhythmia Recurrence and Other Comorbidities. 
The recurrence of an atrial arrhythmia following a previous ablation was 
defined as any atrial arrhythmia lasting longer than 30 seconds in duration as 
monitored on an ECG or Echocardiogram.  
The CHADS2 and the CHA2DS2-VASc scores are both predictors of stroke risk 
in patients with AF, whose scores are used to determine the need for 
anticoagulation therapy (Kalabalik et al. 2015). For CHADS2 score the patient 
receives 1 point for each of the following conditions including congestive heart 
failure (CHF), hypertension, Age (≥75 years), Diabetes mellitus, and prior history of 
Stroke or TIA, except for Stroke, which receives 2 points, for a total of 6 points. 
CHA2DS2-VASc has the same clinical relevance, but succeeds the CHADS2 score for its 
addition of the presence of vascular disease, age (65-74 years), and sex (female), for 
a total of 9 points. 
In the chart review, PVCs were distinguished as being identified on a 
chart/ECG or a Holter/event monitor, but in analyzing the significance of history or 
incident PVC, any PVC regardless of the method of detection was counted as 
sufficient. 
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Statistical Analysis 
Normally-distributed continuous variables were expressed as mean +/- SD 
values and compared by unpaired t-tests with equal variances. All categorical 
variables were expressed as simple proportions and compared by chi-squared tests.  
Cox proportional hazards regression was used to identify statistically 
significant predictors of PVC incidence. Covariates considered for the model were 
selected a priori based on the potential association of the variable with PVC 
development, and were adjusted for in the multivariate models and included: 
demographics (age, sex, race, ethnicity, height, weight, BMI, type of AF), 
comorbidities (pulse, systolic blood pressure, hypertension, hyperlipidemia, chronic 
kidney disease stage, diabetes mellitus, prior cerebrovascular accidents, previous 
thromboembolic events, angina, chronic lung disease, chronic obstructive 
pulmonary disease, congestive heart failure, CHADS2 scores, CHA2DS2-VASC scores, 
coronary artery disease, prior myocardial infarctions, priory 
angioplasty/stent/PCI’s, prior coronary artery bypass graft, prior cardiac valve 
surgery, smoking status, history of hypothyroid and hyperthyroid, chronic 
obstructive pulmonary disease, history of typical and atypical atrial flutter, 
cardioversions post-ablation, history of pacemaker, and history of PVC), and 
procedure information. 
To evaluate the association of incident PVC development and post-blanking 
period recurrence of AF, time-to-event analyses with Kaplan-Meier curves were 
constructed for univariate analyses.  For multivariable analyses, Cox Proportional 
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Hazards regression models were used, adjusting for the same variables used in 
previous multivariable models as potential confounders.   
Statistical tests were 2-sided and considered significant if they yielded a 
value of p<0.05. Analyses were performed using Stata Statistical Software Release 
14 (Stata Corp 2015, College Station, TX). UCSD Human Research Protection 
Program approved analysis of the data from our institution for this study.  
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RESULTS 
 
Primary Outcome and Description of Study Population 
A total of 317 first-time PVI ablation patients were analyzed, and 36.3% 
(n=115) of patients developed PVCs following their PVI procedure. Between the two 
main classifications of AF investigated, paroxysmal and persistent, 74.6% (n=85) of 
those that developed incident PVC had Paroxysmal AF. This does not show a 
significant difference from the proportion of patients with Paroxysmal AF that did 
not develop PVC at 72.9% (n=145). Overall, the total percentage of male, non-
Hispanic, White patients undergoing ablation were 74%, 95.4%, and 96.9%, 
respectively. Continuing, there was no significant difference between incident PVC 
status and factors such as gender, ethnicity and race. 
 
Unadjusted Bivariate Analysis  
In unadjusted univariate analyses, CHADS2 scores were found to be 
significantly different between patients with incident PVCs and no PVCs with mean 
scores of 1.09±0.09 and 0.825±0.07, respectively (p=0.018). Additionally, CHA2DS2-
VASc scores were also found to be significantly different between patients with 
incident PVCs and no PVCs following ablation, with scores of 2.05± 0.14 and 1.61± 
0.10, respectively (p=0.011). The rest of the comorbidities investigated under this 
analysis did not have statistically significant associations with incident PVC status. 
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Unadjusted Bivariate Analysis  
In evaluating the association of incident PVC status with AF-associated risk 
factors, there were multiple factors identified as significant between the two groups 
including: history of PVC, hypertension, angina, and coronary artery disease. A 
history of PVC was seen in 34.5% of patients that developed incident PVC, versus a 
rate of 21.1% in patients without PVCs following ablation (p=0.01). A history of PVC 
was determined to be significant in both unadjusted bivariate analyses as well as 
adjusted multivariate analysis.  Hypertension was seen in 60.5% of patients with 
PVCs following ablation, which was significantly different from the 48.0% of 
patients without PVCs (p=0.033). Angina was seen in only 3.5% of patients with 
incident PVCs, but did not occur in any of the patients that did not develop PVCs 
following ablation (p=0.008). Lastly, coronary artery disease (CAD) was found in 
19.3% of patients with PVCs following ablation, and only 11.2% of patients that did 
not have post-ablation PVCs (p=0.05). The rest of the comorbidities investigated did 
not have statistically significant associations and are elaborated in further detail in 
Appendix B.  
Demographic, clinical, and diagnostic information of all patients comparing 
incident PVC status with are shown in Table 1. 
 
Multivariate Adjusted Analysis 
In multivariable analyses, of the various AF-associated risk factors analyzed, 
patients with a history of PVC were found to have a higher risk of incident PVC 
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development (HR 1.83, 95% CI 1.02- 3.26, p=0.041). Additionally, a history of prior 
angioplasty/Stent/PCI were found to have a lower risk of incident PVC development 
(HR 0.27, 95% CI 0.080-0.88, p=0.030). The rest of the comorbidities investigated 
did not have statistically significant associations and are elaborated in further detail 
in Appendix B. 
 
Time-to-Event Analysis 
It was determined that Incident PVC status did not significantly correlate 
with a risk of recurrent AF (p=0.60). It was also determined that there were no 
significant differences in outcomes of catheter ablation with those that had a history 
of PVC either (p=0.96). Figure 4 and Figure 5 show the survival curves for 
development of recurrent AF against history of PVC and incident PVC status, 
respectively (Appendix A).  
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The mean and standard deviation are defined for the continuous variables and noted in 
the left column. The percentage of each respective population are used to describe 
dichotomous variables in this study. Highlighting denotes statistically significant p -
values, if any. 
Table 1.  Baseline Characteristics of 317 patients with and without incident PVC 
following AF ablation.   
 
Characteristic 
Incident PVC 
(n=115) 
No PVC 
(n=202) 
 
p Value 
Patient Demographics  
Age, mean (SD), years 63.4 (10.9) 60.9 (12.1) 0.066 
BMI 27.6 (5.6) 28.5 (5.7) 0.144 
Female Gender 24.4% 26.9% 0.623 
Race   0.413 
 White 95.2% 97.9%  
 Black/African-American 1.9% 0.5%  
 Asian 2.9% 1.6%  
 Native American/Alaskan 
Native 
0.0% 0.0%  
 Native Hawaiian/Pacific 
Islander 
0.0% 0.0%  
Ethnicity   0.211 
 Non-Hispanic 93.4% 96.6%  
 Hispanic 6.6% 3.4%  
Type of Atrial Fibrillation   0.743 
 Paroxysmal 74.6% 72.9%  
 Persistent 25.4% 27.1%  
Comorbidities 
Pulse, Mean (SD), bpm 71.4 (14.9) 73 (17.6) 0.843 
Systolic Blood Pressure, mmHg 124.5 (16.9) 124.3 (17.7) 0.917 
CHADS2 Score 1.09 (0.09) 0.825 (0.07) 0.018 
CHA2DS2-VASc Score 2.05 (0.14) 1.61 (0.10) 0.011 
History of Typical AFL 34.2% 30.5% 0.505 
History of Atypical AFL 14.9% 12.7% 0.585 
History of PVC 34.5% 21.1% 0.010 
History of stroke 7.0% 6.6% 0.887 
Hypertension 60.5% 48.0% 0.033 
Hyperlipidemia 39.5% 39.3% 0.974 
Diabetes 12.3% 8.6% 0.300 
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Table 1.  Baseline Characteristics of 317 patients with and without incident 
PVC following AF ablation, continued. 
 
Characteristic 
Incident PVC 
(n=115) 
No PVC 
(n=202) 
 
p Value 
 
Comorbidities 
Obstructive Sleep Apnea 12.4% 7.6% 0.165 
Angina 3.5% 0.0% 0.008 
Hypothyroid 11.4% 16.2% 0.253 
Hyperthyroid 1.8% 1% 0.596 
Chronic Lung Disease 0.9% 0.0% 0.188 
Coronary Artery Disease 19.3% 11.2% 0.050 
Chronic Kidney Disease 0.487 
 Stage 1 81.1% 84.2%  
 Stage 2 17.1% 15.3%  
 Stage 3 1.8% 0.5%  
 Stage 4 0.0% 0.0%  
Congestive Heart Failure 0.917 
 None 88.6% 88.3%  
 Reduced Ejection Fraction 6.1% 7.1%  
 Preserved Ejection 
Fraction 
5.3% 4.6%  
CHADS2 Score 0.098 
 0 31.6% 43.5%  
 1 38.6% 37.0%  
 2 21.0% 15.0%  
 3 7.0% 2.5%  
 4 1.8% 2.0%  
CHA2DS2-VASc Score 0.128 
 0 16.6% 25.4%  
 1 25.4% 28.4%  
 2 20.2% 20.4%  
 3 19.3% 17.4%  
 4 12.3% 4.5%  
 5 5.3% 3.0%  
 6 0.0% 0.0%  
 7 0.9% 1.0%  
The mean and standard deviation are defined for the continuous variables and noted in 
the left column. The percentage of each respective population are used to describe 
dichotomous variables in this study. Highlighting denotes statistically significant p -
values, if any. 
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The hazard ratios denote the risk for each respective factor relative to incident PVC 
development, with 95% confidence intervals of each factor. Highlighting denotes 
statistically significant p-values, if any. 
Table 2.  Characteristics Associated with Incident PVC Development Among 
Patients Undergoing AF Ablation 
 
Characteristic 
Hazard Ratio 
(HR) 
95% Confidence 
Interval  
 
p Value 
Patient Demographics  
Age, mean (SD), years 0.998 0.97-1.03 0.950 
BMI 0.997 0.95-1.05 0.931 
Female Gender 0.97 0.45-2.13 0.946 
Race 1.62 0.54-4.81 0.388 
Ethnicity 0.97 0.17-5.57 0.969 
Type of Atrial Fibrillation    
 Persistent 0.71 0.38-1.32 0.279 
Comorbidities 
Pulse 1.00 0.99-1.02 0.900 
Systolic Blood Pressure, mmHg 1.00 0.983-1.01 0.810 
History of PVC 1.83 1.02-3.26 0.041 
History of Typical Atrial Flutter 1.22 0.65-2.27 0.531 
History of Atypical Atrial Flutter 0.87 0.42-1.80 0.707 
Hypertension 1.05 0.42-2.61 0.916 
Hyperlipidemia 0.95 0.51-1.76 0.872 
Diabetes 0.82 0.27-2.49 0.723 
Obstructive Sleep Apnea 1.16 0.50-2.69 0.729 
Angina 2.22 0.48-10.4 0.309 
Hypothyroid 1.25 0.54-2.89 0.599 
Hyperthyroid 0.997 0.09-11.4 0.998 
Smoking 0.39 0.05-3.14 0.377 
Prior Cerebrovascular Event 0.42 0.08-2.29 0.315 
Congestive Heart Failure 0.79 0.37-1.66 0.516 
Pacemaker 0.56 0.18-1.69 0.303 
Chronic Obstructive Pulmonary 
Disease (COPD) 
0.162  0.02-1.69 0.128 
Chronic Kidney Disease 1.53 0.86-2.74 0.145 
CHADS2 Score 1.43 0.69-2.92 0.334 
CHA2DS2-VASc Score 1.10 0.67-1.81 0.703 
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Table 2.  Characteristics Associated with Incident PVC Development Among 
Patients Undergoing AF Ablation, continued. 
 
Characteristic 
Hazard Ratio 
(HR) 
95% Confidence 
Interval  
 
p Value 
Comorbidities 
Coronary Artery Disease 3.07 0.84-11.3 0.091 
History of Myocardial Infarction 1.60 0.38-6.72 0.518 
Prior Coronary Artery Bypass 
Graft (CABG) 
0.15 0.01-1.51 0.107 
Prior angioplasty/Stent/PCI 0.266 0.08-0.877 0.030 
History of Valve Surgery 1.64 0.47-5.72 0.435 
Cardioversion Post-Ablation 0.606 0.298-1.23 0.167 
Recurrent AF 1.09 0.605-1.96 0.775 
The hazard ratios denote the risk for each respective factor relative to incident PVC 
development, with 95% confidence intervals of each factor. Highlighting denotes 
statistically significant p-values, if any. 
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DISCUSSION 
The outcomes of pulmonary vein isolation (PVI) ablation for atrial fibrillation 
have been previously studied and show success rates in the 50-70% range, indicating 
room for improvement in reduction of recurrence (Brooks et al. 2010, Takigawa et al. 
2014, Miyazaki 2011). Previous studies examining mechanisms and triggers that cause 
atrial fibrillation have identified that premature atrial contractions (PACs) may incite the 
arrhythmia, and biologic plausibility would exist for a shared mechanism between PACs 
and PVCs occurring in the same individual (Allessie et al. 2001, Haissaguerre et al. 
1998). Additionally, it has been noted that many risk factors between AF and PVCs are 
shared. Out of the 317 patients reviewed, 36.3% of patients were found to have incident 
PVCs after catheter ablation. This is a higher percentage in comparison to the 11% found 
in the only other study investigating the same relationship (Patel et al. 2014). In 
multivariate adjusted models, two factors were predictive of incident PVCs development 
following catheter ablation for atrial fibrillation, a history of PVCs (HR=1.83, p=0.041) 
and a history of angioplasty/stent/PCI (HR=0.266, p=0.03). These findings are clinically 
meaningful, because they propose a higher rate of PVC development following ablation 
with a larger sample than has been previously described. Only having two significant 
predictors in a long list of known comorbidities with AF implicates the need for future 
investigation of other variables that may have an association with development of PVCs. 
Only one study to date has investigated the relationship between AF patients 
undergoing catheter ablation and incident PVC development. Patel et al. investigated the 
incidence of outflow tract PVCs in 53 patients undergoing AF ablation (Patel et al. 2014). 
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PVCs were found in 11% of the patient population in this study, as well as no significant 
difference in the recurrence of AF following ablation between patients with or without 
PVCs. Our current study differs from the investigation by Patel et al. in its sample size, 
comorbidities investigated, and general outcomes. Patel et al. had a sample size of 53 and 
only looked at a small number of baseline characteristics, compared to the current study’s 
sample size of 317 patients, and many comorbidities investigated. This difference is due 
to the main objectives of each respective study, where Patel et al. investigated incidence 
of PVC and focused on mean heart rate before and after the ablation, and the current 
study investigated incident PVC status and any AF-associated predictors of PVC (Patel et 
al. 2014). With notable limitations, such as a small sample size and a lack of clinical 
outcomes, more could be done to elucidate on this potential relationship. The purpose of 
the current study was to evaluate the incidence of PVC following catheter ablation in a 
large cohort of patients with atrial fibrillation. This analysis also aimed to highlight and 
assess significant predictors of post-ablation incident PVC. 
Overall, the total percentage of males, non-Hispanic, and White patients 
undergoing ablation were 74%, 95.4%, and 96.9%, respectively. These rates 
coincide with the rates of AF prevalence for gender, ethnicity, and race established 
in previous studies. Age was not determined to be significantly different between 
those who did and did not go on to develop PVCs (p=0.066) which may be 
surprising, given that it has been determined that PVC prevalence doubles for 
women and triples for men from ages 45-65 (Simpson Jr et al. 2002). 
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The current study found an incidence of PVC in 25.3% more patients than 
was previously found in the only other study investigating the same relationship 
(Patel et al. 2014). This higher percentage may be due to the underlying 
mechanisms shared between AF and PVC and longer follow-up time allowing for 
detection of these potentially associated arrhythmias. The proportion of patients in 
this study with a history of PVCs that developed incident PVCs was 26.2%. With a 
significant proportion of patients having clinically evident PVCs before ablation, it 
follows that patients with a history of PVC being treated for AF may not necessarily 
lower their burden of PVC. Moreover, the increased proportion of patients with 
incident PVC in comparison to a history of PVC suggests that PVCs either developed, 
or were more readily diagnosed following the PVI procedure. This proportion of 
incident PVC is clinically significant, as many patients following catheter ablation 
may feel palpitations or symptoms similarly experienced with AF, but these 
symptoms could be related to PVCs.  Treating AF with catheter ablation does not 
necessarily preclude the initiation or symptoms of other arrhythmias.  
Through two-sample t-tests with equal variances, the means of CHADS2 and 
CHA2DS2-VASc between incident PVC statuses were determined to be significantly 
different. The mean CHADS2 score in patients with incident PVC in this cohort was 
1.087, with a difference -0.263 from patients that do not develop incident PVC 
(p=0.018; 95% CI -0.479 -0.046). Similarly the mean CHA2DS2-VASc score of 
patients with incident PVC was 2.05, with a difference -0.44 from patients that do 
not develop incident PVC (p=0.011; 95% CI -0.78 -0.104). It has been previously 
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established that stroke rates are higher in patients with a higher burden of PVC 
(Agarwal et al. 2010). Given that both CHADS2 and the CHA2DS2-VASc scores are 
evaluators for risk of stroke, these higher average scores for patients developing 
incident PVC are consistent with the literature. 
In unadjusted bivariate analyses to valuate AF-associated risk factors with 
incident PVCs, there were multiple factors identified as statistically significant. 
Among these factors were History of PVC (p=0.015), hypertension (p=0.033), angina 
(p=0.008), and coronary artery disease (p=0.05). Hypertension is one of the 
previously discussed risk factors that can directly attribute to the changing of 
substrate that propagates AF over time. This finding supports the conjecture that 
PVCs causing arrhythmia in the atria could possibly affect the ventricles in a similar 
manner. The factors that were determined to be non-significant through unadjusted 
bivariate analyses are elaborated in Appendix B. 
 In multivariate adjusted models, two factors were predictive of incident PVCs 
following catheter ablation for atrial fibrillation. A history of PVCs (HR=1.83, 95% CI 
1.02- 3.26, p=0.041) was associated with an increased risk of PVC development 
whereas a history of angioplasty/stent/PCI was associated with a decreased risk of 
PVC development (HR=0.266, 95% CI 0.080-0.88, p=0.03). The increased risk of 
developing PVCs in a population that had a high burden of PVC prior to ablation has 
plausibility, as PVCs are not often targeted during ablation for AF. Future studies 
should investigate if the actual burden of PVC increases after AF ablation and 
whether this is a result of slower ventricular rate in general after maintaining sinus 
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rhythm. That a history of angioplasty/stent/PCI would be protective against 
developing PVCs is intriguing.  This could represent myocardial ischemia as a 
precursor of PVC development, which with resolution by revascularization, may be 
protective against the development of PVCs later on. The factors that were 
determined to be non-significant through multivariate adjusted analysis are 
elaborated in Appendix B. 
 The tertiary outcome of the study was to investigate a time-to-event analysis 
for associated risks between PVC development and the risk of AF recurrence after 
ablation. Rates of AF recurrence following PVI have been documented in various 
studies, but none have investigated the association of PVC development as 
predictors for AF recurrence. We found no significant difference in the recurrence of 
AF for either history (HR= 1.01, 95% CI 0.70-1.46, p=0.96) or incident PVC 
(HR=1.09, 95% CI 0.78-1.53, p=0.6), even after adjustment for potential 
confounders.  
 
Limitations of Incident PVC 
There are several limitations to this study.  First, there is no universal 
definition for incident PVC in the literature, and we used a definition of any PVCs on 
ECG or noted >1% on Holter/event monitor. Future studies should evaluate 
predictors of large burden PVCs.  Second, as in any observational study, there 
remains that possibility that residual confounding explains some of the results of 
this study. 
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CONCLUSIONS 
In 317 patients undergoing pulmonary vein isolation for atrial fibrillation, 
36.3% developed incident PVC following ablation. This is the first study examining 
incident PVCs following AF ablation in a sample size this large. A prior history of 
PVC predicted an increased risk of PVC development (HR=1.83, 95% CI 1.02-3.26, 
p=0.041), and a history of angioplasty, stent, or PCI before the ablation was 
associated with decreased risk of PVC development (HR=0.266, 95% CI 0.08-0.877, 
p=0.030). Neither history of PVC (HR= 1.01, 95% CI 0.70-1.46, p=0.96) nor incident 
PVC development (HR=1.09, 95% CI 0.78-1.53, p=0.6) were risk factors for 
recurrent AF development following ablation.  
Given the mechanisms discussed that may implicate an association between 
AF and PVCs, this research supports the need for future work in determining if 
inciting beats in both the atrium and ventricle are related. That there was such a 
high rate of incident PVCs highlights that there may be relationships with other 
factors that still need to be investigated. 
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APPENDIX A - THE FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A single lead electrocardiogram (ECG) recording of atrial fibrillation 
(AF). The defining clinical features of AF shown here are a distinct lack of p waves, 
which are replaced by fibrillatory (f) waves, as well as the presence of irregular RR 
intervals. (Adapted from UpToDate, 2017) 
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Figure 2. A myocardial action potential. Et is threshold potential and Em is 
resting potential. Each phase is denoted by its respective number. Early 
afterdepolarizations occur between phases 2 and 3, respectively, slowing the 
return to Em. (Adapted from UpToDate, 2017) 
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Figure 3: Single lead electrocardiogram (ECG) showing premature ventricular 
complex (PVC). The fourth beat is a PVC with a wide morphology and a duration 
>0.16 seconds. (Adapted from UpToDate, 2017). 
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Figure 4: Survival curve of patients with AF Recurrence and history of PVC 
status. The blue line represents population of patients without a history of PVC that 
had recurrence of AF, and the red line represents population of patients with a 
history of PVC that had recurrence of AF.   
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Figure 5: Survival curve of patients with AF Recurrence and incident PVC status. 
The blue line represents population of patients without incident PVC development 
that had recurrence of AF, and the red line represents population of patients with 
incident PVC development that had recurrence of AF.   
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APPENDIX B – ADDITIONAL VARIABLES CONSIDERED 
 
While Patel et al. investigated the incidence of PVCs following AF ablation, 
this is the first study to investigate possible predictors of incident PVCs that may be 
associated with AF (Patel et al. 2014). Given the uncertainty of the root of PVCs 
following AF ablation, this study looked at multiple comorbidities that are 
associated with AF that could be gathered through a review of patient medical 
histories.  Many of the factors were selected based on availability of data, and 
overall, the large list of comorbidities chosen was primarily exploratory in nature. 
All of the variables underwent unadjusted bivariate analysis as well as multivariate 
Cox hazard analysis. 
After final bivariate unadjusted analysis, factors that were found to be non-
significant were age (p=0.066), BMI (p=0.144), gender (p=0.623), AF classification 
(p=0.413), Ethnicity (p=0.211), Type of Atrial Fibrillation (0.743), mean pulse 
(p=0.843), systolic blood pressure (p=0.917), History of typical and atypical atrial 
flutter (p=0.505) and (p=0.585), history of stroke (p=0.887), respectively, 
hyperlipidemia (p=0.974), diabetes (p=0.300), obstructive sleep apnea (p=0.165), 
hypothyroid (p=0.253), hyperthyroid (p=0.596), chronic lung disease (0.188), 
chronic kidney disease (p=0.487), CHADS2 score (p=0.334), CHA2DS2-VASc score 
(p=0.703), coronary artery disease (p=0.091), congestive heart failure (p=0917), 
CHADS2 Score (0.098), and CHA2DS2-VASc Score (p=0.128). 
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  After final multivariate adjusted analysis, factors that were found to be non-
significant were age (p=0.950), BMI (p=0.931), gender (p=0.946), AF classification 
(p=0.279), mean pulse (p=0.900), systolic blood pressure (p=0.810), History of 
typical and atypical atrial flutter (p=0.531) and (p=0.707), respectively, 
hypertension (p=0.916), hyperlipidemia (p=0.872), diabetes (p=0.723), obstructive 
sleep apnea (p=0.729), angina (p=0.309), hypothyroid (p=0.599), hyperthyroid 
(p=0.998), smoking (p=0.377), prior cerebrovascular events (p=0.315), congestive 
heart failure (p=0.516), pacemaker (p=0.303), chronic obstructive pulmonary 
disease (p=0.128), chronic kidney disease (p=0.145), CHADS2 score (p=0.334), 
CHA2DS2-VASc score (p=0.703), coronary artery disease (p=0.091), history of 
myocardial infarction (p=0.518), prior coronary artery bypass graft (p=0.107), 
history of valve surgery (p=0.435),  cardioversion post-ablation (p=0.167), and 
recurrent AF (p=0.775). 
 While a history of PVC was found to be significant in both types of analyses, 
bivariate unadjusted analyses found significance in CHADS2 scores (p=0.018), 
CHA2DS2-VASc scores (p=0.011), hypertension (p=0.033), angina (p=0.008), and 
coronary artery disease (p=0.050). This is in stark contrast with the one other 
significant predictor found through multivariate analysis, which was a history of 
angioplasty, stent, or PCI (p=0.030). Given that the multivariate analysis only had 
two significant predictors, it would be of interest to expand the database to 
encompass a large sample size, and determine if any other predictors are found. 
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